Zhongnan Medical Journal Press

Home Results

A total of 27 result was found. Results that relate to Economic

Cost-utility analysis of pembrolizumab combined with chemotherapy for advanced malignant pleural mesothelioma

Published on Chinese Journal of Pharmacoepidemiology 2024,33(10):1107-1114.
9013 times 1665 times

HU Yunjia ZOU Keqing HOU Yanhong

Pembrolizumab Chemotherapy Advanced malignant pleural mesothelioma Partitioned survival model Cost-utility analysis Pharmacoeconomic evaluation
Details
Economic evaluation of multi-station drug dispensing robots for intravenous infusion preparation

Published on Chinese Journal of Pharmacoepidemiology 2024,33(12):1375-1381.
16111 times 1354 times

SUN Zhihong ZHAO Shaoliang ZHOU Furong LIU Feiyu WANG Pengcheng ZOU Shaohua GUO Chenyu

Multi-station dispensing robot Pharmacy intravenous admixture services Dispensing efficiency Cost-effectiveness analysis Economic evaluation
Details
Pharmacoeconomic evaluation of third-line treatment of advanced non-small cell lung cancer with anlotinib

Published on Frontiers in Pharmaceutical Sciences 2024,28(4):639-647.
10478 times 1185 times

YUAN Wenjie KANG Shuo WANG Xiaohui GONG Yuan PAN Zhenhua

Anlotinib Pharmacoeconomics Non-small cell lung cancer Cost-utility analysis
Details
Visualization analysis of research hotspots of the economic burden of acute ischemic stroke

Published on Chinese Journal of Pharmacoepidemiology 2025,34(1):78-85.
8101 times 1199 times

BAI Yitong ZHAO Zhigang GUAN Zhongjun

Acute Ischemic Stroke Economic Burden Bibliometric Analysis Visualization analysis
Details
Cost-effectiveness analysis of low-dose steriod combined with tacrolimus or cyclophosphamide in the treatment of adult idiopathic membranous nephropathy

Published on Chinese Journal of Pharmacoepidemiology 2025,34(2):175-181.
8774 times 1188 times

GUO Shanshan GUO Li LI Jiandong ZHENG Xijie CHEN Hang

Steroid Tacrolimus Idiopathic membranous nephropathy Decision tree model Pharmacoeconomics
Details
Analysis of the latent profiles and influencing factors of subjective economic toxicity in chronic patients

Published on New Medicine 2025,35(3):262-270.
5854 times 1242 times

ZHANG Zhen WEI Shiyi TIAN Yanzhen WU Yanxian CHEN Zhengying TIAN Liwen

Chronic diseases Economic toxicity Latent profile analysis Influencing factors
Details
Pharmacoeconomic evaluation of ribociclib plus fulvestrant in second-line treatment of HR+/HER2- advanced breast cancer for postmenopausal women

Published on Chinese Journal of Pharmacoepidemiology 2025,34(6):612-620.
7585 times 1149 times

JIA Caifeng WANG Jie ZHANG Sen WANG Meiqi LI Sainan WANG Mingxia

Ribociclib Fulvestrant Advanced breast cancer Postmenopausal Pharmacoeconomic evaluation Cost-effectiveness analysis
Details
Sugemalimab as first-line treatment for non-small cell lung cancer: a rapid health technology assessment

Published on Chinese Journal of Pharmacoepidemiology 2025,34(7):806-814.
6426 times 927 times

HOU Yibing KANG Shuo GONG Yuan WANG Xiaohui NIE Ying LIU Huanlong

Sugemalimab Non-small cell lung cancer Effectiveness Safety Economics Rapid health technology assessment
Details
Cost-utility analysis of albumin paclitaxel combined with atezolizumab for the treatment of PD-L1-positive advanced triple-negative breast cancer

Published on Frontiers in Pharmaceutical Sciences 2025,29(7):1179-1185.
6664 times 794 times

HU Xiuping TAN Lunan LI Hongbo YAO Huitao

Albumin paclitaxel Atezolizumab Pharmacoeconomics Cost-utility analysis
Details
Sinicization and reliability and validity testing of the Chronic Disease Economic Toxicity Scale

Published on New Medicine 2025,35(8):940-946.
4465 times 849 times

ZHU Xiaoling WANG Lang TIAN Yanzhen ZHANG Zhen WEI Shiyi LI Qingfeng LONG Yanhong TANG Jie

Chronic disease Financial toxicity Chronic Disease Economic Toxicity Scale Transcultural adaptation Reliability Validity
Details
Analysis of the impact of international research on dose rounding of anti-tumor drugs on the cost of anti-tumor drugs in China

Published on Frontiers in Pharmaceutical Sciences 2025,29(12):2065-2071.
1297 times 229 times

REN Lingzhi YU Wenhao WANG Ting TANG Min ZHOU Ziyuan TANG Haochun MENG Jun

Anti-tumor drugs Dose rounding Drug cost Cost saving Healthcare expenses Economic burden Monoclonal antibody
Details
Clinical efficacy and pharmacoeconomic evaluation of compound Fengshining tablets in treating knee osteoarthritis

Published on Chinese Journal of Pharmacoepidemiology 2026,35(1):31-38.
607 times 171 times

LU Wencan YANG Zili LI Xian

Knee osteoarthritis Compound Fengshining tablets Traditional Chinese medicine syndrome Inflammatory factors Pharmacoeconomics
Details